13.50

0.77% -0.12

10 X Genomics Inc (TXG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.62

Offen:

$13.47

24-Stunden-Volumen:

1.60M

Relative Volume:

0.42

Marktkapitalisierung:

$1.50B

Einnahmen:

$631.73M

Nettoeinkommen (Verlust:

$-239.78M

KGV:

-6.6832

EPS:

-2.02

Netto-Cashflow:

$-33.45M

1W Leistung:

+8.55%

1M Leistung:

+24.10%

6M Leistung:

-8.74%

1J Leistung:

-28.76%

1-Tages-Spanne:

$13.26

$13.88

1-Wochen-Bereich:

$11.45

$14.03

52-Wochen-Spanne:

$6.78

$24.76

10 X Genomics Inc Stock (TXG) Company Profile

Firmenname

10 X Genomics Inc

Sektor

Healthcare (1167)

Branche

Health Information Services (53)

Telefon

(925) 401-7300

Adresse

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Mitarbeiter

1,306

Twitter

@10xgenomics

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

TXG's Discussions on Twitter

Vergleichen Sie TXG mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TXG 10 X Genomics Inc	13.51	1.60B	631.73M	-239.78M	-33.45M	-2.02
VEEV Veeva Systems Inc	290.73	46.61B	2.86B	780.66M	1.20B	4.72
TEM Tempus Ai Inc	63.34	10.57B	803.32M	-709.10M	-212.68M	-7.8003
DOCS Doximity Inc	60.56	11.13B	550.17M	201.35M	232.07M	1.00
HQY Healthequity Inc	95.23	8.42B	1.15B	96.70M	-161.99M	1.09
WAY Waystar Holding Corp	37.23	6.33B	906.14M	-52.62M	89.62M	-0.3621

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-13	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-03	Eingeleitet	Leerink Partners	Outperform
2024-07-22	Hochstufung	Jefferies	Hold → Buy
2024-07-18	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-10	Herabstufung	Deutsche Bank	Buy → Hold
2024-06-27	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Herabstufung	Guggenheim	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-05-01	Herabstufung	TD Cowen	Buy → Hold
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Hochstufung	BofA Securities	Underperform → Neutral
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-05-10	Eingeleitet	Barclays	Overweight
2023-03-31	Eingeleitet	Stephens	Overweight
2023-02-02	Eingeleitet	UBS	Neutral
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-08-18	Herabstufung	Goldman	Neutral → Sell
2022-07-25	Eingeleitet	Canaccord Genuity	Buy
2022-07-15	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-15	Herabstufung	William Blair	Outperform → Mkt Perform
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-09-14	Herabstufung	BofA Securities	Buy → Neutral
2021-03-15	Eingeleitet	William Blair	Outperform
2020-12-02	Eingeleitet	Goldman	Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-07-10	Eingeleitet	Stifel	Buy
2020-03-05	Eingeleitet	Guggenheim	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-07	Eingeleitet	BofA/Merrill	Buy
2019-10-07	Eingeleitet	Cowen	Outperform
2019-10-07	Eingeleitet	JP Morgan	Overweight
2019-09-24	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

Jul 23, 2025

What analysts say about 10x Genomics Inc. stockOutperformance with explosive growth - Autocar Professional

Jul 23, 2025

Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance

Jul 23, 2025

Jul 22, 2025

Is 10x Genomics Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com

Jul 22, 2025

10x Genomics Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025

What drives 10x Genomics Inc. stock priceBreakout profit opportunities - jammulinksnews.com

Jul 22, 2025

Jul 18, 2025

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study - Agency for Science, Technology and Research

Jul 18, 2025

Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know - Yahoo Finance

Jul 18, 2025

Jul 17, 2025

10x Genomics Ends UPC Patent Fight With Bruker - Law360

Jul 17, 2025

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery - the-scientist.com

Jul 17, 2025

Jul 14, 2025

Why 10x Genomics Inc. stock attracts strong analyst attentionFree Market Sentiment Analysis - beatles.ru

Jul 14, 2025

Jul 11, 2025

Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - Yahoo Finance

Jul 11, 2025

10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace

Jul 11, 2025

Jul 03, 2025

10x Genomics, Inc.(NasdaqGS: TXG) dropped from Russell 1000 Value Index - MarketScreener

Jun 30, 2025

Jun 29, 2025

10x Genomics, Inc.(NasdaqGS: TXG) dropped from Russell 1000 Dynamic Index - MarketScreener

Jun 29, 2025

Jun 27, 2025

10x Genomics (TXG) Receives a Hold from Bank of America Securities - The Globe and Mail

Jun 27, 2025

Jun 26, 2025

10x Genomics (TXG) Analyst Maintains Rating but Raises Price Target | TXG Stock News - GuruFocus

Jun 26, 2025

Jun 23, 2025

Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG) - Yahoo Finance

Jun 23, 2025

Jun 22, 2025

11 Best Genomics Stocks to Buy According to Hedge Funds - Insider Monkey

Jun 22, 2025

Jun 20, 2025

Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 31% - simplywall.st

Jun 20, 2025

Jun 18, 2025